Table 2.
Outcomes Across Arms
| Notification Arm N=86 |
Usual Care N=87 |
p-value | |
|---|---|---|---|
| Statin Discussion/Prescription, 3 months | 53 (64.6%) | 7 (8.4%) | <0.001 |
| Statin Discussion/Prescription, 6 months | 67 (77.9%) | 10 (12.0%) | <0.001 |
| Statin Prescription, 6 weeks | 7 (35.0%) | 0 (0.0%) | 0.008 |
| Statin Prescription, 3 months | 32 (39.0%) | 4 (4.8%) | <0.001 |
| Statin Prescription, 6 months | 44 (51.2%) | 6 (6.9%) | <0.001 |
| Statin Intensity | <0.001 | ||
| High-Intensity | 8 (9.3%) | 3 (3.4%) | |
| Moderate-Intensity | 32 (37.2%) | 3 (3.4%) | |
| Low-Intensity | 4 (4.7%) | 0 (0.0%) | |
| No Statin | 42 (48.8%) | 81 (93.1%) | |
| Secondary Outcomes*,† | |||
| Aspirin Treatment, 6 months | 16 (18.6%) | 17 (19.5%) | 0.848 |
| New Aspirin Treatment, 6 months‡ | 7/74 (9.5%) | 7/75 (9.3%) | 0.879 |
| Number of anti-hypertensives, 6 months | 0 (0-1) | 0 (0-2) | 0.985 |
| Hemoglobin A1c Measured, follow-up | 29 (33.7%) | 23 (26.4%) | 0.211 |
| Hemoglobin A1c, % (Non-missing), follow-up | 5.7 (0.7) | 5.5 (0.5) | 0.107 |
| Lipids Measured, follow-up§ | 50 (58.1%) | 29 (33.3%) | 0.002 |
| Low-Density Lipoprotein (LDL), mg/dL (Non-missing), follow-up | 97.2 (30.3) | 115.3 (29.4) | 0.005 |
| LDL <70mg/dL | 9 (10.5%) | 2 (2.3%) | |
| LDL 70-99 mg/dL | 20 (23.3%) | 6 (6.9%) | |
| LDL 100-129 mg/dL | 12 (14.0%) | 12 (13.8%) | |
| LDL ≥130 mg/dL | 9 (10.5%) | 9 (10.3%) | |
| Missing LDL | 36 (41.9%) | 58 (66.7%) | |
| High-Density Lipoprotein, mg/dL (Non-missing), follow-up | 64.2 (21.6) | 61.7 (22.5) | 0.872 |
| Triglycerides, mg/dL (Non-missing), follow-up | 87.1 (40.7) | 123.4 (70.8) | 0.009 |
| Systolic Blood Pressure Measured, follow-up§ | 69 (80.2%) | 64 (73.6%) | 0.287 |
| Systolic Blood Pressure, mmHg (Non-missing), follow-up | 131.3 (17.4) | 128.9 (15.0) | 0.374 |
| Body Mass Index Measured, follow-up§ | 66 (76.7%) | 63 (72.4%) | 0.486 |
| Body Mass Index, kg/m2 (Non-Missing), follow-up | 25.5 (5.1) | 26.7 (5.6) | 0.630 |
Abbreviations: ASCD: atherosclerotic cardiovascular disease.
*
For secondary outcomes of lab values, vitals, anti-hypertensives, and aspirin treatment, statistical testing is adjusted for baseline value and age. For lab testing, statistical testing is adjusted for age. Results with imputation via last observation carried forward and multiple imputation available in Supplement Table 2.
†
Aspirin and number of antihypertensives based on assessment at 6 months post-notification. All other outcomes based on last assessment during the 6-month follow-up period.
‡
New aspirin treatment among those not on treatment at baseline.
§
Defined as a measurement during the 6-month follow-up period.